Alerts will be sent to your verified email
Verify EmailBLISSGVS
|
Bliss GVS Pharma
|
Novartis
|
Indoco Remedies
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
R&D as a % of Total Sales
|
2.7 % | n/a | 5.7 % |
|
Financials
|
|||
|
5 yr Average ROE
|
6.83 % | 8.0 % | 8.94 % |
|
5yr average Equity Multiplier
|
1.3 | 2.72 | 1.9 |
|
5yr Average Asset Turnover Ratio
|
0.62 | 0.18 | 0.88 |
|
5yr Avg Net Profit Margin
|
8.7 % | 17.12 % | 5.41 % |
|
Price to Book
|
1.62 | 2.44 | 1.99 |
|
P/E
|
16.72 | 19.42 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
186.56 Days | -23.33 Days | 35.3 Days |
|
Inventory Days
|
54.35 Days | 44.27 Days | 70.6 Days |
|
Days Receivable
|
189.93 Days | 38.18 Days | 83.16 Days |
|
Days Payable
|
75.78 Days | 124.28 Days | 111.01 Days |
|
5yr Average Interest Coverage Ratio
|
14.68 | 65.43 | 7.53 |
|
5yr Avg ROCE
|
13.27 % | 5.91 % | 13.6 % |
|
5yr Avg Operating Profit Margin
|
17.03 % | 15.15 % | 14.97 % |
|
5 yr average Debt to Equity
|
0.11 | 0.0 | 0.49 |
|
5yr CAGR Net Profit
|
4.24 % | 37.01 % | n/a |
|
5yr Average Return on Assets
|
5.31 % | 3.13 % | 5.31 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
35.36 % | 70.68 % | 58.9 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.9 % | 0.0 | 0.21 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.27 % |
|
Bliss GVS Pharma
|
Novartis
|
Indoco Remedies
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|